Cardiogen vs MK-677
Moderate Research vs Well Studied
synergistic Mechanism-based · 47% Cardiogen and MK-677 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Cardiogen MK-677
Weight 460 Da 624.77 Da
Half-life Minutes (short peptide); effects persist via epigenetic changes ~24 hours
Chain 4 amino acids —
Type Tetrapeptide bioregulator Non-peptide ghrelin receptor agonist
Key Benefits
Cardiogen
01 Supports cardiac tissue repair and regeneration
02 Regulates cardiovascular gene expression
03 Improves myocardial function
04 May support post-cardiac event recovery
05 Epigenetic mechanism for targeted action
06 Works at DNA/nuclear level
07 Part of comprehensive anti-aging protocols
08 Well-researched Khavinson peptide
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Dosing Protocols
Cardiogen
10-20 mg daily / Once daily for 10-20 consecutive days
Research protocol 10 mg Daily for 10 days
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Side Effects
Cardiogen
Generally well-tolerated
Minimal side effects reported
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Contraindications
Active cardiac emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Research Evidence
Cardiogen MK-677
Status Moderate Research Well Studied
References 3 studies 7 studies
Latest — July 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.